Log In
BCIQ
Print this Print this
 

edasalonexent (CAT-1004)

  Manage Alerts
Collapse Summary General Information
Company Catabasis Pharmaceuticals Inc.
DescriptionConjugate of salicylate and docosahexaenoic acid (DHA) that inhibits activated NF-kappa B (NF-kB)
Molecular Target Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 (NF-kB) (NFKB1) (p105) (p50)
Mechanism of ActionNF-kappa B (NF-kB) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/29/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today